Invivyd (NASDAQ:IVVD) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS
by Michael Walen · The Markets DailyInvivyd (NASDAQ:IVVD – Get Free Report) issued its earnings results on Monday. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.03, FiscalAI reports. Invivyd had a negative net margin of 183.90% and a negative return on equity of 59.73%. The business had revenue of $15.45 million for the quarter, compared to analyst estimates of $15.04 million.
Invivyd Trading Down 7.6%
IVVD stock opened at $0.54 on Tuesday. Invivyd has a 1-year low of $0.52 and a 1-year high of $3.07. The firm has a fifty day moving average price of $0.72 and a two-hundred day moving average price of $1.08.
Wall Street Analyst Weigh In
A number of equities analysts recently commented on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Invivyd in a research note on Thursday, August 27th. Weiss Ratings raised Invivyd from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, September 8th. HC Wainwright restated a “buy” rating on shares of Invivyd in a research note on Tuesday, September 29th. Finally, BTIG Research reaffirmed a “buy” rating on shares of Invivyd in a report on Monday. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $10.00.
Check Out Our Latest Stock Analysis on Invivyd
About Invivyd
Invivyd is a biotechnology company focused on developing antibody-based medicines to help prevent and treat infectious diseases, with an emphasis on COVID-19. Its work includes discovering and engineering monoclonal antibodies intended to retain activity against changing viral variants. The company’s lead product, pemivibart, is marketed in the United States as PEMGARDA. The U.S. Food and Drug Administration authorized it for emergency use as pre-exposure prevention of COVID-19 in certain people with moderate-to-severe immune compromise who may not have an adequate response to vaccination.
Read More
- Five stocks we like better than Invivyd
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook